Skip to main content
Year archive

NEUROTECH INTERNATIONAL LIMITED — 2023 filings

All 76 regulatory filings released by NEUROTECH INTERNATIONAL LIMITED (NTI) in 2023, sourced directly from the official regulator.

76 Filings
2023 Period
2023 filings (76)
Filing Released Lang
Phase II/III Autism Clinical Trial Completes Recruitment 2 pages 187.2KB
Regulatory Filings
2023-12-18 English
Application for quotation of securities - NTI 6 pages 27.9KB
Share Issue/Capital Change
2023-12-18 English
Secondary Trading Notice 1 page 93.7KB
Regulatory Filings
2023-12-18 English
Change in substantial holding 2 pages 300.5KB
Major Shareholding Notification
2023-12-04 English
HREC Approval to Extend Phase II/III ASD Trial to Adults 2 pages 183.9KB
Regulatory Filings
2023-12-03 English
Change of Director's Interest Notice x 2 5 pages 353.3KB
Director's Dealing
2023-11-30 English
Application for quotation of securities - NTI 6 pages 27.9KB
Share Issue/Capital Change
2023-11-29 English
Investor Presentation 20 pages 2.7MB
Investor Presentation
2023-11-21 English
Chairman's Address to 2023 Annual General Meeting 2 pages 114.0KB
AGM Information
2023-11-14 English
2023 Annual General Meeting Presentation 17 pages 2.0MB
AGM Information
2023-11-14 English
Results of Meeting 2 pages 113.7KB
Declaration of Voting Results & Voting Rights Announcements
2023-11-14 English
New Constitution 75 pages 1.1MB
Regulatory Filings
2023-11-14 English
Neurotech Receives $3.17 Million R&D Tax Incentive Refund 1
Capital/Financing Update
2023-11-13 English
Q&A on Phase I/II PANDAS/PANS Clinical Trial Results 4 pages 176.4KB
Regulatory Filings
2023-10-31 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 434.7KB
Interim / Quarterly Report
2023-10-26 English
Notice of Quarterly Investor Conference Call 2 pages 103.9KB
Regulatory Filings
2023-10-23 English
Notice of Annual General Meeting/Proxy Form 27 pages 666.4KB
Proxy Solicitation & Information Statement
2023-10-15 English
Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint 10 pages 213.9KB
Investor Presentation
2023-10-05 English
Investor Presentation - PANDAS/PANS Clinical Trials Results 23 pages 1.9MB
Investor Presentation
2023-10-05 English
Trading Halt 2 pages 520.1KB
Regulatory Filings
2023-10-03 English
Completion of Patient Recruitment in NTIRTT1 Clinical Trial 3 pages 195.9KB
Regulatory Filings
2023-09-25 English
Annual Report (Typeset) 76 pages 8.2MB
Annual Report
2023-09-21 English
Application for quotation of securities - NTI 6 pages 28.5KB
Capital/Financing Update
2023-09-17 English
Secondary Trading Notice 1 page 96.4KB
Regulatory Filings
2023-09-17 English
Appointment of Corporate Advisor 2 pages 96.0KB
Capital/Financing Update
2023-09-14 English
Proposed issue of securities - NTI 7 pages 35.1KB
Capital/Financing Update
2023-09-14 English
Clinician Briefing Presentation and Webcast 19 pages 2.2MB
Investor Presentation
2023-09-14 English
Proposed issue of securities - NTI 5 pages 27.2KB
Capital/Financing Update
2023-09-14 English
Upcoming Clinician Briefing 3 pages 172.2KB
Investor Presentation
2023-09-10 English
Last Patient Completes Treatment in NTIPANS1 Clinical Trial 2 pages 147.2KB
Regulatory Filings
2023-08-30 English
Appendix 4E & Annual Report 72 pages 1.3MB
Annual Report
2023-08-29 English
Appendix 4G and Corporate Governance Statement 28 pages 412.4KB
Regulatory Filings
2023-08-29 English
Application for quotation of securities - NTI 6 pages 27.9KB
Share Issue/Capital Change
2023-08-07 English
Disclosure Document 31 pages 332.6KB
Capital/Financing Update
2023-08-03 English
Proposed issue of securities - NTI 5 pages 27.3KB
Capital/Financing Update
2023-08-03 English
First Patient Treated in Rett Syndrome Clinical Trial 2 pages 190.4KB
Regulatory Filings
2023-07-31 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 430.3KB
Interim / Quarterly Report
2023-07-25 English
Notice of Quarterly Investor Conference Call 2 pages 147.0KB
Regulatory Filings
2023-07-18 English
NTI Receives HREC Approval for Rett Syndrome Clinical Trial 6 pages 233.3KB
Regulatory Filings
2023-07-09 English
Notification of cessation of securities - NTI 5 pages 25.1KB
Share Issue/Capital Change
2023-06-29 English
Notification regarding unquoted securities - NTI 11 pages 48.3KB
Capital/Financing Update
2023-06-27 English
NTI to Present at Rett Syndrome Foundation Meeting 2 pages 124.2KB
Regulatory Filings
2023-06-04 English
Results of Meeting 3 pages 112.5KB
Declaration of Voting Results & Voting Rights Announcements
2023-05-31 English
NTI Granted 2 Year Extension of Treatment for ASD Patients 2 pages 197.9KB
Regulatory Filings
2023-05-30 English
NTI granted HREC Approval for PANDAS/PANS Trial Extension 2 pages 187.4KB
Regulatory Filings
2023-05-29 English
Notification of cessation of securities - NTI 4 pages 23.9KB
Share Issue/Capital Change
2023-05-15 English
NTI Completes Recruitment in PANDAS/PANS Clinical Trial 2 pages 143.4KB
Regulatory Filings
2023-05-02 English
Notice of General Meeting/Proxy Form 33 pages 1.0MB
Proxy Solicitation & Information Statement
2023-04-30 English
Notification of cessation of securities - NTI 6 pages 27.6KB
Regulatory Filings
2023-04-30 English
Proposed issue of securities - NTI 10 pages 48.6KB
Capital/Financing Update
2023-04-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 315.4KB
Interim / Quarterly Report
2023-04-26 English
Notice of Quarterly Investor Conference Call 2 pages 104.3KB
Regulatory Filings
2023-04-25 English
NTI to Launch Phase II Clinical Trial in Rett Syndrome 3 pages 195.8KB
Capital/Financing Update
2023-03-19 English
Investor Presentation 24 pages 2.6MB
Investor Presentation
2023-03-19 English
Neurotech to Present at NWR Virtual Healthcare Conference 1
Investor Presentation
2023-03-19 English
Phase I/II ASD Clinical Trials Results at 52 Weeks 12 pages 341.1KB
Capital/Financing Update
2023-03-16 English
Investor Presentation 26 pages 2.4MB
Investor Presentation
2023-03-16 English
Investor Conference Call - 52 Week Autism Study Results 2 pages 116.8KB
Regulatory Filings
2023-03-16 English
Trading Halt 2 pages 514.5KB
Regulatory Filings
2023-03-14 English
Notification of cessation of securities - NTI 5 pages 25.6KB
Regulatory Filings
2023-02-28 English
Appendix 4D and Half Year Accounts 25 pages 494.1KB
Interim / Quarterly Report
2023-02-27 English
Notification regarding unquoted securities - NTI 9 pages 33.4KB
Share Issue/Capital Change
2023-02-27 English
First Patient Treated in Phase I/II PANDAS/PANS Trial 2 pages 176.6KB
Regulatory Filings
2023-02-15 English
Approval for Additional Phase I/II ASD Trial Extension 2 pages 176.8KB
Regulatory Filings
2023-02-13 English
Application for quotation of securities - NTI 8 pages 30.0KB
Share Issue/Capital Change
2023-01-30 English
Distribution Schedule 1 page 63.7KB
Major Shareholding Notification
2023-01-30 English
Top 20 securityholders 2 pages 67.9KB
Major Shareholding Notification
2023-01-30 English
Application for quotation of securities - NTI 9 pages 32.5KB
Capital/Financing Update
2023-01-30 English
Secondary Trading Notice 1 page 92.8KB
Capital/Financing Update
2023-01-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 725.4KB
Interim / Quarterly Report
2023-01-29 English
HREC Approval for Phase I/II PANDAS/PANS Clinical Trial 6 pages 203.6KB
Regulatory Filings
2023-01-26 English
Notice of Quarterly Investor Conference Call 2 pages 102.0KB
Regulatory Filings
2023-01-23 English
Application for quotation of securities - NTI 8 pages 29.6KB
Share Issue/Capital Change
2023-01-23 English
Secondary Trading Notice 1 page 92.8KB
Capital/Financing Update
2023-01-23 English
NTI Granted FDA Pre-IND Meeting for NTI164 in ASD 2 pages 172.6KB
Regulatory Filings
2023-01-18 English
Extension of Offers under Prospectus 2 pages 106.5KB
Capital/Financing Update
2023-01-12 English